恩替卡韦联合护肝片治疗慢性乙型肝炎肝硬化的疗效分析

Efficacy Analysis of Entecavir Combined with Liver-protectin Tablets in the Treatment of Chronic Hepatitis B Cirrhosis

目的:探讨恩替卡韦联合护肝片治疗慢性乙型肝炎肝硬化的疗效。方法:选取2019年2月-2021年2月中山市人民医院收治的慢性乙型肝炎肝硬化患者50例为观察对象,依据随机数表法分为对照组和观察组,各25例。对照组采用恩替卡韦治疗,观察组采用恩替卡韦联合护肝片治疗,比较两组总有效率和治疗前后肝功能指标、肝纤维化指标水平、血清细胞因子水平、乙型肝炎病毒基因(HBV-DNA)。结果:观察组总有效率高于对照组,差异具有统计学意义(P<0.05);治疗后,观察组患者肝功能、肝纤维化指标水平均低于对照组,差异具有统计学意义(P<0.05);观察组血清细胞因子水平低于对照组,差异具有统计学意义(P<0.05);治疗1个月、2个月、3个月后,观察组HBV-DNA低于对照组,差异具有统计学意义(P<0.05)。结论:对慢性乙型肝炎肝硬化患者采用恩替卡韦联合护肝药物治疗可提高治疗总有效率,改善患者的肝功能指标,降低纤维化程度水平与血清细胞因子水平。

Objective:To investigate the efficacy of entecavir combined with Liver-protectin tablets in the treatment of chronic hepatitis B cirrhosis.Methods:Fifty patients with chronic hepatitis B cirrhosis who were admitted to Zhongshan People's Hospital from February 2019 to February 2021 were selected as the observation objects.According to the random number table method,they were divided into control group and observation group,with 25 cases in each group.The control group was treated with entecavir,and the observation group was treated with entecavir combined with Liver-protectin tablets.The total effective rate,liver function indexes,liver fibrosis index levels,serum cytokine levels,and hepatitis B virus gene(HBV-DNA)before and after treatment were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of liver function and liver fibrosis indexes in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The serum cytokine levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After 1 month,2 months and 3 months of treatment,the HBV-DNA of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:Entecavir combined with liver-protecting drugs in patients with chronic hepatitis B cirrhosis can improve the total effective rate of treatment,improve the liver function indexes,and reduce the level of fibrosis and serum cytokines.